A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
PHASE1RecruitingINTERVENTIONAL
Enrollment
56
Participants
Timeline
Start Date
May 26, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
May 31, 2027
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
DRUG
ABO2203 Injection
SC or IV
Trial Locations (1)
200025
RECRUITING
Ruijin Hospital, Shanghai
All Listed Sponsors
lead
Ruijin Hospital
OTHER
NCT07072169 - A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) | Biotech Hunter | Biotech Hunter